Zobrazeno 1 - 10
of 210
pro vyhledávání: '"Lizhu Lin"'
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-19 (2024)
Abstract Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) constitute essential component
Externí odkaz:
https://doaj.org/article/29c31094a70d4814be3ab0065887f458
Autor:
Yi Bao, Yaxin Chen, Lizhu Lin, Jingyi Li, Xinli Liu, Gang Wang, Yueqi Li, Yao Lin, Yajing Chen, Lijuan Zhou, Yawen Qi, Yufang Xie, Zhenrui Lin, Zhe Sun, Yuwen Fan, Jinjing Jiang, Feiyu Zhang, Hubin Chen, Jiemei Chu, Jiegang Huang, Xuena Chen, Hao Liang, Shuaiyi Liang, Sanqi An
Publikováno v:
iMeta, Vol 3, Iss 3, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/37002c3263634204927a10997d122a92
Autor:
Jianchun Duan, Wenfeng Fang, Hairong Xu, Jinliang Wang, Yuan Chen, Yi Ding, Xiaorong Dong, Yun Fan, Beili Gao, Jie Hu, Yan Huang, Cheng Huang, Dingzhi Huang, Wenhua Liang, Lizhu Lin, Hui Liu, Zhiyong Ma, Meiqi Shi, Yong Song, Chuanhao Tang, Jialei Wang, Lifeng Wang, Yongfeng Wang, Zhehai Wang, Nong Yang, Yu Yao, Yan Yu, Qitao Yu, Hongmei Zhang, Jun Zhao, Mingfang Zhao, Zhengfei Zhu, Xiaohui Niu, Li Zhang, Jie Wang
Publikováno v:
Journal of the National Cancer Center, Vol 3, Iss 4, Pp 256-265 (2023)
Lung cancer is the leading cause of cancer-related deaths worldwide. Bone is a common metastatic site of lung cancer, about 50% of bone metastatic patients will experience skeletal related events (SREs). SREs not only seriously impact the quality of
Externí odkaz:
https://doaj.org/article/64c371bf622d46b68856e83b202c08a9
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Savolitinib is a highly selective mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor (TKI). Based on its significant efficacy shown in clinical studies, savolitinib was conditionally approved for marketing in China on 22 June 2021, for
Externí odkaz:
https://doaj.org/article/ad17572f3e474f928a39c738c824f793
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Posterior reversible encephalopathy syndrome (PRES), a neurological disorder with an unknown aetiology, is characterised by visual impairment, headache, vomiting, seizures, and transient alterations in consciousness.Case report: We presen
Externí odkaz:
https://doaj.org/article/ef17ca1197b24afa9f52135a1d7d8e0d
Autor:
Qi Li, Tailai An, Jianbin Wu, Weiqi Lu, Yan Wang, Jia Li, Lina Yang, Yiqi Chen, Lizhu Lin, Zhenjiang Yang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background The impact of sarcopenia on the outcome of patients with left-sided colon and rectal cancer has not been exhaustively investigated. Thus, the present study was performed to evaluate the effect of sarcopenia on the outcome of patie
Externí odkaz:
https://doaj.org/article/92320256953d487f9d440e5dd9d7f23b
Autor:
Hongmei Tang, Qin Lu, Shiyin Feng, Zhiwei Xiao, Wanyin Wu, Gaofeng Chen, Li Deng, Tianqi Yu, Junyan Wu, Hua Lin, Bo Ji, Jietao Lin, Chengguang Zhang, Liming Li, Tao Liu, Yong Ouyang, Kaijun Lei, Jun Chen, Weiwen Peng, Zhenwen Qiu, Qingqun Cai, Qi Liang, Cuiling Liu, Yuzhen Li, Lixia Zhu, Zexin Zhang, Xueting Liu, Lizhu Lin, Zhihua Zheng
Publikováno v:
Pharmaceutical Biology, Vol 62, Iss 1, Pp 472-479 (2024)
AbstractContext The Xihuang pill (XHP) is a traditional Chinese medicine formulation that has been historically used in the prevention and treatment of proliferative breast diseases. However, there is a lack of guidelines that offer recommendations f
Externí odkaz:
https://doaj.org/article/d876a83d78b542b48da286f7185304dc
Autor:
Yi‐Long Wu, Shun Lu, Qinghua Zhou, Li Zhang, Ying Cheng, Jie Wang, Buhai Wang, Chengping Hu, Lizhu Lin, Wenzhao Zhong, Yong Song, Nong Yang, Xiaorong Dong, Jian Zhao, Haihong Yang, Hui Guo, Xiaolong Yan, Hongxu Liu, Rui Ma, Jie Lin, Siyang Liu, Chun Chen, Lifeng Wang, Chengzhi Zhou, Ming Zhou, Fang Wu, Xue‐Ning Yang, Yingying Du, Yu Yao, Yang Shao, Shaodong Hong, Jiuwei Cui, Xueping Quan, Rongrong Chen, Jiayan Wu, Jiatao Zhang, Jianya Zhou, Binchao Wang, Chao Cheng, Huijuan Wang, Jingjing Liu, Lin Wu, Yan Huang, Yukun Kuang, Yongchang Zhang, Jia Hu, Jinji Yang, Weineng Feng, Wenmei Su, Yun Fan, Fan Yang, Ming Chen, Kejing Tang, Yi Pan, Peng Shen, Anwen Liu, Haibo Zhang, Wenhua Liang, Qing Zhou, Zhiyong Ma, Xiuyu Cai, Hui Liu, Longfei Chen, Shaokun Chuai, Jianzhen Shan, Yanfang Zheng, Changxuan You, Xiaoxia Zhu, Li Li, Tongmei Zhang, Haiyan Tu, Wurong Lin, Xuchao Zhang, Penghui Zhou, Zunfu Ke, Huiying Liang
Publikováno v:
Medicine Advances, Vol 1, Iss 1, Pp 3-13 (2023)
Abstract Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation
Externí odkaz:
https://doaj.org/article/628a61c2e0b7401888cbceb96adb32ce
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Paraneoplastic Cushing’s syndrome (PCS) is a rare, but clinically important feature of small cell lung cancer (SCLC) that is associated with even worse prognosis. To identify key considerations in comprehensive management of SCLC patients complicat
Externí odkaz:
https://doaj.org/article/2fd4d22caeb04d38b983990b521446a4
Autor:
Fengying Wu, Tao Jiang, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Tao Zhang, Wei Shi, Jianjun Zou, Xuejuan Bai, Shengxiang Ren, Caicun Zhou, the CameL Study Group
Publikováno v:
Cancer Communications, Vol 42, Iss 12, Pp 1331-1346 (2022)
Abstract Background Although programmed cell death 1 (PD‐1) blockade plus chemotherapy can significantly prolong the progression‐free survival (PFS) and overall survival (OS) in first‐line settings in patients with driver‐negative advanced no
Externí odkaz:
https://doaj.org/article/29c625b2073e4405bfa35cd6c6aed633